Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;10(6):1544-56.
doi: 10.4161/hv.28704. Epub 2014 Apr 14.

Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population

Affiliations

Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population

Sudeep Karve et al. Hum Vaccin Immunother. 2014.

Abstract

This study assessed and described the episode rate, duration of illness, and health care utilization and costs associated with acute gastroenteritis (AGE), norovirus gastroenteritis (NVGE), and rotavirus gastroenteritis (RVGE) in physician office, emergency department (ED), and inpatient care settings in the United States (US). The retrospective analysis was conducted using an administrative insurance claims database (2006-2011). AGE episode rates were assessed using medical (ICD-9-CM) codes for AGE; whereas a previously published "indirect" method was used in assessing estimated episode rates of NVGE and RVGE. We calculated per-patient, per-episode and total costs incurred in three care settings for the three diseases over five seasons. For each season, we extrapolated the total economic burden associated with the diseases to the US population. The overall AGE episode rate in the physician office care setting declined by 15% during the study period; whereas the AGE episode rate remained stable in the inpatient care setting. AGE-related total costs (inflation-adjusted) per 100 000 plan members increased by 28% during the 2010-2011 season, compared with the 2006-2007 season ($832,849 vs. $1 068 116) primarily due to increase in AGE-related inpatient costs. On average, the duration of illness for NVGE and RVGE was 1 day longer than the duration of illness for AGE (mean: 2 days). Nationally, the average AGE-related estimated total cost was $3.88 billion; NVGE and RVGE each accounted for 7% of this total. The episodes of RVGE among pediatric populations have declined; however, NVGE, RVGE and AGE continue to pose a substantial burden among managed care enrollees. In conclusion, the study further reaffirms that RVGE has continued to decline in pediatric population post-launch of the rotavirus vaccination program and provides RVGE- and NVGE-related costs and utilization estimates which can serve as a resource for researchers and policy makers to conduct cost-effectiveness studies for prevention programs.

Keywords: acute gastroenteritis; duration of illness; health care cost; norovirus; rotavirus.

PubMed Disclaimer

Figures

None
Figure 1. Acute Gastroenteritis, Norovirus and Rotavirus-Related Total Costs per 100,000 Plan Members in Physician’s Office, Emergency Department, and Inpatient Care Setting, by Seasons. AGE = acute gastroenteritis; ED = emergency department; US = United States.

Similar articles

Cited by

References

    1. Hall AJ, Rosenthal M, Gregoricus N, Greene SA, Ferguson J, Henao OL, Vinjé J, Lopman BA, Parashar UD, Widdowson M-A. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004-2005. Emerg Infect Dis. 2011;17:1381–8. - PMC - PubMed
    1. Jones TF, McMillian MB, Scallan E, Frenzen PD, Cronquist AB, Thomas S, Angulo FJ. A population-based estimate of the substantial burden of diarrhoeal disease in the United States; FoodNet, 1996-2003. Epidemiol Infect. 2007;135:293–301. doi: 10.1017/S0950268806006765. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. burden of norovirus illness and outbreaks [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; c2012 [updated 2013 September 27; cited 2013 Jun 18]; [about 2 screens]. Available from: http://www.cdc.gov/norovirus/php/illness-outbreaks.html
    1. Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen) Hum Vaccin. 2011;7:563–8. doi: 10.4161/hv.7.5.15406. - DOI - PubMed
    1. O’Ryan M, Linhares AC. Update on Rotarix: an oral human rotavirus vaccine. Expert Rev Vaccines. 2009;8:1627–41. doi: 10.1586/erv.09.136. - DOI - PubMed

Publication types

MeSH terms